# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001731122-21-000572
Filing Date
2021-04-12
Accepted
2021-04-12 16:06:04
Documents
5
Period of Report
2021-04-12

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | e2624_def14a.htm | DEF 14A | 289491
2 | GRAPHIC | e2572annexa_1.jpg | GRAPHIC | 484621
3 | GRAPHIC | e2572annexa_2.jpg | GRAPHIC | 371571
4 | GRAPHIC | e2572proxy_1.jpg | GRAPHIC | 307847
5 | GRAPHIC | e2572proxy_2.jpg | GRAPHIC | 346564
| Complete submission text file | 0001731122-21-000572.txt |  | 2370631

Mailing Address 51 W 52ND STREET, 7TH FLOOR NEW YORK NY 10019-6163
Business Address 51 W 52ND STREET, 7TH FLOOR NEW YORK NY 10019-6163 800-689-3939
ANAVEX LIFE SCIENCES CORP. (Filer) CIK: 0001314052 (see all company filings)

EIN.: 208365999 | State of Incorp.: NV | Fiscal Year End: 0930
Type: DEF 14A | Act: 34 | File No.: 001-37606 | Film No.: 21820797
SIC: 8731 Services-Commercial Physical & Biological Research